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Objective: To investigate the clinicopathological features of primary intravascular large B-cell lymphoma of lung.
Methods: A case of primary pulmonary intravascular large B-cell lymphoma was analysed in histopathology and
immunophenotype.
Results: The patient is a 42-year-old female who had cough for one year. Computed tomography showed ground-
glass opacities and small nodules in bilateral lung fields. Histopathology demonstrated accumulation of similar sized
neoplastic cells within alveolar capillaries, widening the alveolar septae. The alveolar structure sustained in part of
districtions. Immunohistologically, the tumor cells were positive for CD20 and negative for CD3,CK, which were
similar to the diffuse large B-cell lymphoma.
Conclusions: Intravascular large B-cell lymphoma is an uncommon type of non-Hodgkin’s lymphoma. Primary
pulmonary presentation is even more rare. The diagnosis is based on the histopathology and
immunohistochemistry.
Virtual slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/
vs/2076991810705433.
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Intravascular large B-cell lymphoma (IVLBCL) is a rare
type of extranodal large B-cell lymphoma characterized
by the selective growth of lymphoma cells within the lu-
mina of vessels, particularly within capillaries, with ex-
ception of larger arteries and veins [1]. The clinical
presentation is highly variable due to occlusion of small
vessels or capillaries in different organ systems. This is
an aggressive lymphoma with poor prognosis which in
part reflects frequent delays in diagnosis due to above
variable symptoms. The most common clinical manifes-
tations involve central nervous system (CNS) presenta-
tions, cutaneous leisions, fever of unknown origin, or
hemophagocytic syndrome. Although autopsy findings
have revealed that pulmonary involvement is common
in this disease, primary presentation in the lungs is* Correspondence: chestpathology@126.com
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reproduction in any medium, provided the ordistinctly uncommon and has been rarely described. We
here reported a case that manifested predominantly as
clinical interstitial lung disease and finally proven
IVLBCL by biopsy. To our knowledge, this maybe the
first case of primary IVLBCL in the lung. The clinical
features, histopathological characteristics, and differen-
tial diagnosis of primary IVLBCL were also discussed in
this article.Case presentation
Patient and methods
The patient was a 42-year-old chinese woman who pre-
sented with nonproductive cough and occasional short-
ness of breath for one year. She had no prior history of
lung disease, and no exposure to occupational or dust
hazards. No focal findings were noted on examination es-
pecially of skin and CNS when the patient consulted our
hospital. Her routine laboratory findings were unevent-
ful. CT showed diffused ground glass opacities and scat-
tered reticulonodular shadow infiltrated bilateral lungs
(Figure 1). No superficial and deep lymphadenopathyThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 chest CT-scan showed diffused interstitial shadows.
Table 1 Panel of Antibodies
Antigen clone Dilution Source
Cytokeratin AE1/AE3 1:200 Dako
Desmin D33 1:200 Gene Tech
Chromogranin A None 1:800 Gene Tech
Cytokeratin 5/6 D5/6 B4 1:100 Gene Tech
vimentin V9 1:200 Dako
S-100 ployclonal 1:2000 Dako
P53 DO-7 1:50 Dako
Cytokeratin 7 OV-TL 1:200 Dako
KI-67 MIB-1 1:300 Dako
Synaptophysin None 1:100 Gene Tech
CD3 polyclonal 1:200 Dako
TTF-1 8G7G3/1 1:200 Dako
CD20 L26 1:400 Gene Tech
SP-A 32E12 1:200 Gene Tech
SP-B 19 H7 1:100 ChangDao
CD34 QBEnd/10 1:200 ChangDao
Actin 1 H4 1:200 ChangDao
Figure 2 Hematoxylin-eosin staining of pulmonary interstitium
intravascular lymphoma (100X).
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brain MRI. She was diagnosed with interstitial penumo-
nitis and treated with antibiotics by our physician. But
after transient improvement of symptoms, the treatment
was not effective and the chest CT-scan showed diffused
interstitial shadows remained. She then went to surgery
for pulmonary biopsy. In the operation, there was no ad-
hesion between the lungs and the chest walls, the whole
lungs showed very tiny granules, no mass was seen in the
lungs. The tissues of lingular segment of left superior
lobe, basal segment and dorsal segment of left inferior
lobe were resected and sent to pathology for diagnosis.
Tissue sections were fixed in 10 % formalin and
hematoxylin and eosin (H & E) stains were supplemen-
ted. Immunohistochemical studies were conducted in
selected formalin-fixed, paraffin-embedded blocks of
case. A Leica autostainer (Bond Max) using a standard
avidin-biotin peroxidase complex technique (with block-
ing of endogenous biotin) was used for immunohisto-
chemical studies. Heat-induced epitope retrieval was
applied as pretreatment for selected markers. Diamino-
benzidine was utilized as the chromogen. The primary
antibodied have been summarized in Table 1. Appropri-
ate positive and negative controls were run concurrently
for all the markers tested.
Results
Gross pathology findings
(1.) Lingular segment of left superior lobe (1.4 x 1.3 x
0.6 cm) showed gray white color and median
texture.
(2.) Basal segment of left inferior lobe (2.6 x 1.5 x
0.5 cm).
(3.) Dorsal segment of inferior lobe (2 x 1.5 x 0.5 cm), a
grayish white node was seen in the incisal surface(1
x 0.7 x 0.3 cm), with clear margin.Histopathology
Part of alveolar structure remained in these resections
with mediastinal widening. The large atypical tumour
cells were mainly lodged in the lumina of small pulmon-
ary arterioles, venules, capillaries, and lymphatics in
cluster (Figure 2 and 3). The neoplastic cells were ir-
regular shaped with prominent nucleoli. They showed
large, vesicular, indented nuclei, eosinophilic nucleoli
and moderate amount of pale cytoplasm. Mitoses in-
cluding atypical forms were seen frequently. Minimal
extravascular location of neoplastic cells also can be
seen. The perivascular regions contained and admixture
of small lymphocytes, plasma cells, and histocytes. The
Figure 3 Hematoxylin-eosin staining of pulmonary interstitium
intravascular lymphoma (400X),the the alveolar septae was
widen and filled with tumour cells showed in high power field.
Figure 5 CD34 immunostain shows the neoplastic lymphocytes
located in the alveolar capillaries,(200X).
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superficially resembled an interstitial pneumonia,
leukemia, or metastatic carcinoma.Immunohistochemistry
The tumor cells were highlighted by staining for
common leukocyte antigen and B-cell marker CD20
(Figure 4). The tumor cells exhibited no immunoreac-
tivity for CKpan, CK7, CK5/6, SPA, SPB, TTF-1 and for
T-cell marker CD3. And no staining was seen with CD34
(Figure 5), S-100protein, Syn, Chr-A, actin, or desmin,Figure 4 CD20 immunostain of the neoplastic intravascular B
lymphocytes (400X).either. Proliferative marker, KI-67 showed distinctive nu-
clear reaction involving 70 % neoplastic cells (Figure 6).
Follow-up
The patient refused to have chemotherapy treatment
after the IVLBCL diagnosis made. She died after
20 months.
Conclusions
By the new World Health Organization (WHO) classifi-
cation, IVLBCL is a rare type of extranodal large B-cell
lymphoma characterized by the selective growth of
lymphoma cells within the lumina of vessels, particularly
capillaries, with exception of larger arteries and veinsFigure 6 KI-67 immunostain highlights the proliferation of
intravascular lymphoma cells, (200X).
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proliferation of clonal lymphocytes with little to no par-
enchymal involvement.
The clinical manifestations of IVLBCL are highly vari-
able and depend on the preferentially involved organs.
There are no pathognomonic, clinical, laboratory, or
radiological signs of IVLBCL. Nearly half of cases
present fever of unknown origin, night sweats, malaise,
fatigue, unexplained weight loss. Anemia, high lactic
acid,dehydrogenase levels, and high sedimentation rates
are typical. In Western countries, CNS and cutaneous
symptoms account for close to 80 % of presentations,
while in Asian countries, hemaphagocytic syndrome are
much more commonly seen. And some authors found
that 68 % of IVLBCL patients had symptoms present in
at least one of these organs. Although autopsy findings
indicated that lung involvement in IVLBCL is relatively
frequent (approximately 60 %) [2], predominat or pri-
mary presentation in lung has been rare. Diagnosis for
our patient was so difficult because she did not demon-
strate any cutaneous or neurological symptoms. Only
chest CT revealed diffuse interstitial changes. Then she
was treated with antibiotics and after transient improve-
ment of symptoms, the treatment was not effective and
the chest CT-scan remained shadows. For the purpose
of diagnosis, surgical lung biopsy was performed. All bi-
opsied specimens demonstrated obstruction of the small
vessels by large neoplastic lymphoid cells, which
expressed B-cell associated antigen CD20. These histo-
logical findings confirmed the diagnosis of IVLBCL.
Radiological examinations in pulmonary IVLBCL
present various findings. The majority of cases with lung
involvement showed diffuse interstitial infiltrates, pleural
effusion, signs of pulmonary hypertension, or consolida-
tion in the lung. In this case, our patient did not demon-
strate any cutaneous or neurological symptoms. The
laboratory findings were normal. And except her chest
CT appeared interstitial pneumonitis alike, there was no
involvement of any other organ considered typical of
IVLBCL. All of these made the diagnosis challenging
and difficult. Recently, FDG-PET has emerged as a
powerful functional imaging tool in the assessment of
patients with non-Hodgkin’s lymphoma (NHL). Several
authors have reported that FDG-PET is useful for the
diagnosis of IVLBCL when this type of lymphoma is
clinically suspected. FDG-PET is a powerful tool for the
early diagnosis of IVLBCL with pulmonary involvement,
if the possibility of this disease presents in the patient
with respiratory symptoms without abnormal findings by
CT [3,4].
IVLBCL is characterized by a massive intravascular
proliferation of atypical mononuclear cells which lodged
in the lumina of small or intermediate vessels in many
organs. The neoplastic lymphoid cells are large withprominent nucleoli and frequent mitotic figures. Fibrin
thrombi, haemorhage and necrosis may be seen. IVLBCL
needs to be differentiated from venous thromboembol-
ism, bland thrombus mixed with lymphoma cells, meta-
static carcinoma or melanoma. The other differential
diagnosis of intravascular malignancy in the lung
includes lymphomatoid granulomatosis, angiocentric
lymphoma, sarcoma, and pulmonary involvement by
acute and chronic lymphocytic leukemias. Immunohisto-
chemistry will provide great help for the correct diagno-
sis. In this case, the neoplastic cells showed ground or
oval shape with large, vesicular nuclei, and little to mod-
erate amounts of pale cytoplasm. No adhesion was seen
between tumor cell. Neuroendocrine tumor and other
mesenchymal differentiated tumors (smooth muscle tis-
sue, neuro tissue et al.) can not be excluded. So we per-
form antibodies like Syn, Chr-A, desmin, S-100 to help
differentiation diagnosis.
The mechanism of selective intravascular location of
IVLBCL are largely unknown. Several studies showed
that the defective interactions between lymphoma cells
and vessels may play a role in the pathogenesis of this
disorder [5–7]. Lymphocyes circulating in the blood ves-
sels bind to high endothelial venules (HEV) with
lymphocyte homing receptor, traverse vessels walls and
enter lymphoid organs. They also found that IVLBCL
cells had normal levels of lymphocyte homing receptor,
while the presence of HEV is selectively low or absent in
organs where IVLBCL commonly occurs, such as brain
and skin. These observations suggest that a deficiency of
HEV in particular sites of blood vessels may block
lymphoma cells transvascular passage and result in the
unusual intravascular location of lymphoma cells. CD29
and CD54 are key molecules for transvascular trafficking
and migration. Recently, it was found that IVLBCL cells
express low levels of CD29 and CD54, which may be re-
sponsible for the selective growth of IVLBCL. In
addition, IVLBCL cells have lower levels of another ad-
hesion molecule CD18, which may also contribute to
their inability to extravasate [8]. CXCL9-CXCR3 also
provide a possible new clue to the pathogenesis of
IVLBCL by virtue of the characteristic expression of
them. CXCR3 was expressed in IVLBCL and its ligand,
CXCL9, was expressed in blood vessels, which might ex-
plain the aggregation of atypical lymphocytes in the vas-
cular lumen [9].
Patients with IVLBCL are thought to have a systemic
disease with an aggressive clinical course [10]. The site
of disease influences the prognosis. Patients with CNS
involvement at initial diagnosis developed early CNS
progression. Conversely, the duration between initial
diagnosis and CNS recurrence was long in patients with-
out CNS involvement [11]. These findings might reflect
differences in clinical manifestations between patients
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The latter have a significantly longer survival. Combin-
ation chemotheraphy is the mainstay of treatment.
CHOP or CHOP-like therapy has been more commonly
offered. The addition of rituximab to CHOP therapy
substantially improved the prognosis of IVLBCL. But the
difficulties and delays in diagnosis oftern result in the
poor prognosis which make it urgent need to better
understand this lymphoma and to optimize its thera-
peutic management.
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